Supriya Lifescience Ltd
NSE:SUPRIYA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
295.75
806.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Supriya Lifescience Ltd
Supriya Lifescience Ltd
Current Portion of Long-Term Debt
Supriya Lifescience Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Supriya Lifescience Ltd
NSE:SUPRIYA
|
Current Portion of Long-Term Debt
₹4.7m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Current Portion of Long-Term Debt
₹41.2B
|
CAGR 3-Years
256%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Current Portion of Long-Term Debt
₹2.4B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-17%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Current Portion of Long-Term Debt
₹22B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Current Portion of Long-Term Debt
₹16.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Current Portion of Long-Term Debt
₹231.2m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Supriya Lifescience Ltd
Glance View
Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2021-12-28. The company focuses on products in various therapeutic segments, such as Anti-Histamine, Anti-Allergics, Vitamins, Anesthetics and Anti-Asthmatics. Its manufacturing facilities include delineated areas for quality check (QC); manufacturing areas with multiple clean rooms; engineering and maintenance; warehouse; materials and finished goods stores; in-house microbiological laboratory, and functional waste treatment plant. The company handles chemical reactions, such as Friedel Craft’s Acylation, Claisen Condensation, Grignard Reaction, Mannich Reaction, Ritter Reaction, Eschweiler Clark reaction, Hydrogenation, Chlorination, Bromination, Decyanation, Isocyanation, Ethoxylation, Nitration, Alkylation, Reduction, Oxidation, Etherification, Chlorosulphonation, Phosphorylation, Chiral resolution, Heterocyclic chemistry, Thermal ring expansion and Protection/Deprotection.
See Also
What is Supriya Lifescience Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
4.7m
INR
Based on the financial report for Mar 31, 2024, Supriya Lifescience Ltd's Current Portion of Long-Term Debt amounts to 4.7m INR.
What is Supriya Lifescience Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
-64%
Over the last year, the Current Portion of Long-Term Debt growth was 32%. The average annual Current Portion of Long-Term Debt growth rates for Supriya Lifescience Ltd have been -44% over the past three years , -64% over the past five years .
You don't have any saved screeners yet
